Symbols

KTTA

Pasithea·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Consensus Rating "Strong Buy"

Bullish Abandoned Baby

RSI Oversold

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KTTA

Pasithea Therapeutics Corp.

A biotech company focused on developing psychedelic-based therapeutics for mental health disorders

Industry

Biological Technology

Established Date

05/12/2020

Listing Date

09/15/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.pasithea.com

Security Type

Common stock

Office address

1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139

Business

Introduction

Pasithea Therapeutics Corp. was incorporated in Delaware on May 12, 2020. The Company is a clinical-stage biotechnology company focused on the discovery, research and development of innovative therapies for central nervous system diseases and other diseases, including RASopathies.

Company Financials

EPS

KTTA has released its 2025 Q2 earnings. EPS was reported at -0.66, versus the expected 0, missing expectations. The chart below visualizes how KTTA has performed over recent quarters, highlighting trends in earnings surprises.